BR112022026396A2 - Arimoclomol para o tratamento da doença de gaucher - Google Patents

Arimoclomol para o tratamento da doença de gaucher

Info

Publication number
BR112022026396A2
BR112022026396A2 BR112022026396A BR112022026396A BR112022026396A2 BR 112022026396 A2 BR112022026396 A2 BR 112022026396A2 BR 112022026396 A BR112022026396 A BR 112022026396A BR 112022026396 A BR112022026396 A BR 112022026396A BR 112022026396 A2 BR112022026396 A2 BR 112022026396A2
Authority
BR
Brazil
Prior art keywords
arimoclomol
disease
gaucher
treatment
piperidinyl
Prior art date
Application number
BR112022026396A
Other languages
English (en)
Portuguese (pt)
Inventor
Kirkegaard Jensen Thomas
Mørkeberg Hinsby Anders
Kolster Fog-Tønnesen Cathrine
Ingemann Linda
Í Dali Christine
Original Assignee
Kempharm Denmark As
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Kempharm Denmark As filed Critical Kempharm Denmark As
Publication of BR112022026396A2 publication Critical patent/BR112022026396A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
BR112022026396A 2020-06-24 2021-06-24 Arimoclomol para o tratamento da doença de gaucher BR112022026396A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP20182067 2020-06-24
PCT/EP2021/067366 WO2021260120A1 (en) 2020-06-24 2021-06-24 Arimoclomol for treating gaucher disease

Publications (1)

Publication Number Publication Date
BR112022026396A2 true BR112022026396A2 (pt) 2023-03-14

Family

ID=71143584

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112022026396A BR112022026396A2 (pt) 2020-06-24 2021-06-24 Arimoclomol para o tratamento da doença de gaucher

Country Status (14)

Country Link
US (1) US20230226036A1 (cg-RX-API-DMAC7.html)
EP (1) EP4171559B1 (cg-RX-API-DMAC7.html)
JP (3) JP2023531750A (cg-RX-API-DMAC7.html)
KR (1) KR20230035586A (cg-RX-API-DMAC7.html)
CN (1) CN116075305A (cg-RX-API-DMAC7.html)
AU (1) AU2021295437A1 (cg-RX-API-DMAC7.html)
BR (1) BR112022026396A2 (cg-RX-API-DMAC7.html)
CA (1) CA3183559A1 (cg-RX-API-DMAC7.html)
DK (1) DK4171559T3 (cg-RX-API-DMAC7.html)
ES (1) ES3056005T3 (cg-RX-API-DMAC7.html)
IL (1) IL299250A (cg-RX-API-DMAC7.html)
MX (1) MX2023000033A (cg-RX-API-DMAC7.html)
PT (1) PT4171559T (cg-RX-API-DMAC7.html)
WO (1) WO2021260120A1 (cg-RX-API-DMAC7.html)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9662375B2 (en) * 2010-11-30 2017-05-30 Orphazyme Aps Methods for increasing intracellular activity of Hsp70

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HU222994B1 (hu) 1995-11-02 2004-01-28 BIOREX Kutató és Fejlesztő Rt. Hidroxilaminszármazékok és azok alkalmazása sejtek molekuláris chaperon-termelésének fokozására alkalmas gyógyszerkészítmények előállítására
HUP9900475D0 (en) 1999-02-26 1999-04-28 Biorex Kutato Fejlesztoe Kft O-(3-piperidino-2-hydroxy-1-propyl)-hiyroximic acid-halogenid derivative, it's use for treating insulin resistance, and pharmaceutical compositions containing them as active component
HUP0001583A2 (hu) 2000-04-18 2002-11-28 BIOREX Kutató és Fejlesztő Rt. Egy piridin-1-oxid-származék és eljárás annak átalakítására gyógyászati hatású vegyületekké
JP5616336B2 (ja) * 2008-06-26 2014-10-29 オルファザイム エーピーエスＯｒｐｈａｚｙｍｅ Ａｐｓ 酵素活性の調節因子としてのＨｓｐ７０の使用
AU2010281403B2 (en) * 2009-07-28 2016-03-10 Takeda Pharmaceutical Company Limited Compositions and methods for treating Gaucher disease
US10709700B2 (en) * 2014-09-15 2020-07-14 Orphazyme A/S Arimoclomol formulation
ES2831764T3 (es) * 2016-04-29 2021-06-09 Orphazyme As Arimoclomol para el tratamiento de trastornos asociados a glucocerebrosidasa
KR102279347B1 (ko) * 2016-12-15 2021-07-21 한국생명공학연구원 피리딘계 화합물을 유효성분으로 함유하는 dyrk 관련 질환의 예방 또는 치료용 약학적 조성물

Also Published As

Publication number Publication date
IL299250A (en) 2023-02-01
AU2021295437A1 (en) 2023-02-02
EP4171559A1 (en) 2023-05-03
KR20230035586A (ko) 2023-03-14
MX2023000033A (es) 2023-04-10
WO2021260120A1 (en) 2021-12-30
JP7849574B2 (ja) 2026-04-21
JP2026042936A (ja) 2026-03-11
JP2023531750A (ja) 2023-07-25
EP4171559B1 (en) 2025-09-10
ES3056005T3 (en) 2026-02-17
CN116075305A (zh) 2023-05-05
CA3183559A1 (en) 2021-12-30
PT4171559T (pt) 2025-12-16
US20230226036A1 (en) 2023-07-20
DK4171559T3 (da) 2025-12-15
JP2026104910A (ja) 2026-06-25

Similar Documents

Publication Publication Date Title
BR112013020005A8 (pt) peptídeo de fórmula geral r1-wn-xm-aa1-aa2-aa3-aa4-aa5-aa6-yp-zq-r2, seus estereoisômeros, misturas dos mesmos e/ou seus sais cosmética ou farmaceuticamente aceitáveis e composição cosmética ou farmacêutica
BRPI0415746A (pt) derivados de amida
BR0009042A (pt) Composto, uso do mesmo, processo para prepararum composto, composição farmacêutica, e, métodospara tratar uma doença em um animal em que aatividade de cisteìna protease contribui para apatologia e/ou sintomatologia da doença, e paratratar uma doença em um animal em que a atividadede catepsina s contribui para a patologia e/ousintomatologia da doença
BR0012590A (pt) Composto, processo para a preparação do mesmo, formulação farmacêutica, uso de um composto, e, métodos para tratamento ou profilaxia de dor ou desconforto, e para tratamento ou profilaxia de dor neuropática ou central
BR112015029491A2 (pt) derivados de imidazopirrolidinona e seu uso no tratamento de doença
BR112015018252A2 (pt) composição farmacêutica aquosa de dose fixa estável para administração nasal para um ser humano, composição de suspensão aquosa farmacêutica de dose fixa estável para administração nasal para um ser humano, suspensão estável adequada para administração nasal a um ser humano, método para tratar rinite em um ser humano necessitando do mesmo, uso da composição farmacêutica para administração nasal, método para liberar uma composição farmacêutica e kit
BR0315337A (pt) Composto, formulação farmacêutica, e, método para tratar câncer
MX2023007551A (es) Arimoclomol para el tratamiento de la enfermedad de niemann pick, tipo c, en pacientes con mutaciones de sentido erroneo de tipo reticulo endoplasmatico (er).
US20200352886A1 (en) Treatment of pain with topical diclofenac
MX2021014315A (es) Compuestos derivados de 1,3,4-oxadiazol homoftalimida como inhibidores de histona desacetilasa 6, y la composicion farmaceutica que comprende los mismos.
BR112021023110A2 (pt) Métodos de tratamento de síndrome de sjögren com o uso de um inibidor de tirosina quinase de bruton
CL2024003601A1 (es) Nuevas combinaciones terapéuticas para el tratamiento de enfermedades pulmonares intersticiales fibrosantes progresivas.
PE134999A1 (es) Uso de aminometil-cromanos sustituidos para el impedimento de la degeneracion neuronal y para el estimulo de la regeneracion neuronal
BR112023020538A2 (pt) Derivados heterocíclicos, composições farmacêuticas e seus usos no tratamento ou na melhoria de câncer
BR112018070653A2 (pt) ingrediente farmacêutico ativo, e, composição
RU2007137115A (ru) Новые офтальмологические композиции и способы их применения
MX2023000033A (es) Arimoclomol para tratar la enfermedad de gaucher.
DK1091733T3 (da) (-)-Pseudoephedrin som et sympatomimetisk lægemiddel
CN110753543A (zh) 用于治疗帕金森氏病的方法和组合物
BR112022011344A2 (pt) Compostos para tratamento de doença de alzheimer e uso desses compostos
BRPI0415625A (pt) uso de um derivado de halogeneto de ácido hidroxìmico no tratamento de hidroxìmico no tratamento de doenças neurogenerativas
BR112022013227A2 (pt) Inibidores de btk
BR112023018949A2 (pt) Composto, uso do mesmo para tratar anemia falciforme e composição farmacêutica compreendendo o referido composto
AR012751A1 (es) Sales de hidrogeno tartrato de (r) -3-n,n-diciclobutilamino-8-fluoro-3,4 -dihidro-2h-1-benzopiran-5-carboxamida, su uso para la fabricacion de medicamentos para tratar trastornos de snc y trastornos medicos relacionados y procedimiento para la fabricacion de dichas sales
BRPI0412131A (pt) métodos de tratamento de distúrbios oftálmicos, para evitar hemorragia retìnica, perda de acuidade visual, reduzir exsudatos duros e retardar progressão de dano retìnico

Legal Events

Date Code Title Description
B25D Requested change of name of applicant approved

Owner name: ZEVRA DENMARK A/S (DK)